Back to journals
Academic Journal

The American Journal of Drug and Alcohol Abuse

6 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans

This open-label study (n=86) examined the effectiveness of psychedelic-assisted therapy (PAT) among trauma-exposed Special Operations Forces Veterans (SOFV) in Mexico. Results indicated significant improvements in self-reported PTSD symptoms, depression, anxiety, insomnia severity, post-concussive symptoms, satisfaction with life, psychological flexibility, and cognitive functioning from baseline to one-month follow-up. The combination of ibogaine and 5-MeO-DMT assisted therapy showed potential for providing rapid and lasting improvements in mental health functioning, with effects observed up to six months after treatment.

Published
Journal
The American Journal of Drug and Alcohol Abuse
Authors
Davis, A. K., Xin, Y., Sepeda, N. D., Averill, L. A.
Paywallindividual

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives

This quantitative interview study (n=1141) applied a machine learning tool to analyze written reports of psychedelic experiences and predicted whether the participants could reduce substance abuse in response to using psychedelics with a 65% accuracy across three independently trained Natural Language Processing models.

Published
Journal
The American Journal of Drug and Alcohol Abuse
Authors
Cox, D. J., Garcia-Romeu, A., Johnson, M. W.
Open Accessindividual

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

This survey study (n=362) examined the therapeutic potential of 5-MeO-DMT when used in a structured group setting, specifically for depression and anxiety. Results indicate that the majority of participants reported improvements in their conditions, which were associated with the intensity of the mystical experience rather than challenging physical or psychological effects.

Published
Journal
The American Journal of Drug and Alcohol Abuse
Authors
Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., Griffiths, R. R.
Open Accessindividual

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

This observational field study (n=30) investigated the effects of ibogaine on opioid detoxification amongst individuals who sought addiction treatment at a private clinic and found that the treatment had a substantiative effect of reducing drug use up to 1 month, or even up to 12 months amongst select individuals.

Published
Journal
The American Journal of Drug and Alcohol Abuse
Authors
Brown, T. K., Alper, K.
Open Accessindividual

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

This open-label study (n=14, 8 at follow-up) found that treatment with ibogaine resulted in lower addiction (ASI-Lite) and depression (BDI-II) scores up to 12 months later.

Published
Journal
The American Journal of Drug and Alcohol Abuse
Authors
Frampton, C. M., Yazar-Klosinski, B., Nollar, G. E.
Open Accessindividual

Long-term follow-up of psilocybin-facilitated smoking cessation

This follow-up study (n=15) found that at 12 months 67% of participants didn't return to smoking (biologically confirmed). This was 60% at an average of 30-month follow-up. This study is the first (very positive) step in seeing if psilocybin-assisted psychotherapy (PAT) may be viable for people to quit smoking.

Published
Journal
The American Journal of Drug and Alcohol Abuse
Authors
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R.

Quick Facts

Papers Indexed
6
Publisher
Taylor & Francis
Website
Visit